XR-17™ is based on a composite of two derivatives of vitamin A. XR-17 forms particles, or micelles with an API that are just 20 to 60 nanometers in size. A human hair is about 80-100,000 nanometers wide.

Molecules that are poorly soluble in water are enclosed in the micelle core, where they can deploy into the blood. Because XR-17 is well tolerated, it makes treatments involving otherwise insoluble substances possible, without the high risk of the adverse side effects typically associated with commonly used solvents such as hypersensitivity reactions. 

Oasmia’s initial focus for XR-17 is on cancer therapies, but the Company believes XR-17 has potential applications in a wide range of diseases where poorly soluble APIs are a challenge.